Tuberculosis (TB) is the leading cause of death for people living with HIV (PLHIV), affecting 10 million people worldwide and resulting in more than 1.5 million deaths in 2020. Integrating TB preventive treatment (TPT) into the fact-track (FT) model could ensure PLHIV enrolled in FT are included in the rollout of three months of once weekly rifapentine and isoniazid (3HP) and leverage the convenience of multi-month dispensing of both antiretroviral therapy (ART) and TPT. This may increase demand for TPT among recipients of care, leading to enhanced coverage and completion of TPT. ICAP at Columbia University (ICAP) partnered with MoHCC and the Zimbabwe National Network for People Living with HIV (ZNNP+) to assess the feasibility and acceptability of the integration of 3HP into the FT model.